Options offer the potential to make much greater gains in a short amount of time compared to the underlying stock. Let's take a basic look at how they are priced. Read More

Comcast is in acquisition mode and rapidly embracing advanced technologies. But as it seeks new avenues for growth, will this multi-media colossus get stretched too thin? Read More

We discuss the benefits of share repurchases and which companies recently made announcements to do so. Read More

Merck has been a money-making machine for decades, but it faces growing competition and patent expirations. Will this drug giant prevail? Read More

Believe it or not, this seemingly stodgy “old tech” copier company has delivered a 57% total return through the first 10 weeks of 2019. Read More

Home Depot is a DJIA component and steady dividend payer. But do economic headwinds and a cooling housing sector pose threats to this retail icon and its payout? Read More

Pfizer is a growth-and-income stock found in many retirement portfolios. But is the competition from biotech "disruptors" getting too hot for this Big Pharma stalwart? Read More

Chevron is poised to gain from rising crude prices, but the energy sector remains volatile. Can this "super major" overcome the industry's uncertainties? Read More

With FDA Chief Scott Gottlieb's departure, we're already seeing big price swings in stocks that may be affected by a change in FDA policy towards tobacco and health care companies. Read More

As the largest health insurer in the U.S., UnitedHealth Group is poised to greatly benefit from booming health care expenditures. But do proposed government policy changes threaten the stock? Read More